TransCelerate BioPharma
See the following -
CDISC and TransCelerate Announce New Standard for Breast Cancer to Support Data Sharing for Oncology Research
The need to rapidly and efficiently share new data in cancer research was recently, and powerfully, highlighted by U.S. Vice President Joe Biden as part of the Cancer Moonshot initiative. The Clinical Data Interchange Standards Consortium (CDISC) and TransCelerate BioPharma, Inc. (“TransCelerate”) announce today the open availability of a new CDISC Therapeutic Area (TA) Standard for Breast Cancer. The CDISC global TA standards can streamline the way clinical research is conducted so that data can be readily shared among clinicians, researchers and regulators around the world, thus leading to more rapid and “smarter” research...
- Login to post comments
CDISC Announces Launch Of CDISC eSHARE
The Clinical Data Interchange Standards Consortium (CDISC) is pleased to announce the official launch of CDISC eSHARE. For the first time, CDISC metadata standards in multiple formats are now electronically accessible by computer applications through an integrated system...
- Login to post comments
TransCelerate Identifies Pharmacovigilance as an Operational Challenge in Need of Transformation
TransCelerate BioPharma Inc. today announced that it has added Pharmacovigilance to its portfolio, establishing two new global initiatives: 1.) Interpretation of Pharmacovigilance Regulations and 2.) Value of Safety Information Data Sources. Both initiatives aim to create solutions that will reduce resource inefficiencies, enhance information exchange with global health authorities and improve patient safety to drive more value for patients...
- Login to post comments